2018年EASL肝脏会议上杨梅展示HBV数据

StephenW

Arbutus to Present HBV Data at 2018 EASL Liver Meeting
Share
Print
March 28, 2018 17:54 ET | Source: Arbutus Biopharma Corporation

VANCOUVER, British Columbia and WARMINSTER, Pa., March 28, 2018 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced presentation of data at the 53rd Annual International Liver Congress of the European Association for the Study of the Liver (EASL) to be held on April 11-15, 2018 at the Paris Porte de Versailles in Paris, France.

"Our data to be presented this year at EASL demonstrates the value of our novel agents and highlights the reasons we are excited about advancing our candidates into the clinic,” said Dr. Mark J. Murray, Arbutus' President and CEO. “Our next-generation capsid inhibitor and novel HBV RNA destabilizer have demonstrated potential for inclusion in a drug combination regime with current standard of care and other Arbutus clinical candidates, further supporting our goal of delivering a curative regimen for patients with chronic HBV.”

Presentations Include:

    April 12, 2018, 4:30pm —4:45pm (CET), HBV Cure: Pre-clinical studies
    Parallel Session Oral Presentation #3503: “Preclinical Antiviral Drug Combination Studies Utilizing Novel Orally Bioavailable Investigational Agents for Chronic Hepatitis B Infection: AB-506, a Next Generation HBV Capsid Inhibitor, and AB-452, a HBV RNA Destabilizer” by Rene Rijnbrand, VP Head of Biology at Arbutus Biopharma
     
    April 12, 2018, 5:00pm —5:15pm (CET), HBV Cure: Pre-clinical studies
    Parallel Session Oral Presentation #2646: “Durable Inhibition of Hepatitis B Virus Replication and Antigenemia Using Subcutaneously Administered siRNA Agent AB-729 in Preclinical Models” by Amy Lee, Senior Director, Research at Arbutus Biopharma

About Arbutus

Arbutus Biopharma Corporation is a publicly traded (Nasdaq:ABUS) biopharmaceutical company dedicated to discovering, developing, and commercializing a cure for patients suffering from chronic Hepatitis B Virus (HBV) infection. Arbutus is developing multiple drug candidates, each of which have the potential to improve upon the standard of care (SOC) and contribute to a curative combination regimen to improve patient outcomes and deliver a potential cure for HBV. For more information, visit www.arbutusbio.com.

StephenW

2018年EASL肝脏会议上杨梅展示HBV数据
分享
打印
2018年3月28日17:54 ET |来源：Arbutus生物制药公司

温哥华，不列颠哥伦比亚省和宾夕法尼亚州温梅斯特，2018年3月28日 - 业界领先的乙型肝炎病毒（HBV）治疗解决方案公司Arbutus Biopharma Corporation（Nasdaq：ABUS）今天宣布，欧洲肝脏研究协会第53届年度国际肝脏大会（EASL）将于2018年4月11日至15日在法国巴黎凡尔赛宫举行。

“我们今年将在EASL上展示的数据证明了我们新型代理商的价值，并突出了我们为推动我们的候选人进入诊所感到兴奋的原因，”Arbutus总裁兼首席执行官Mark J. Murray博士说，“我们的下一个 - 生成的衣壳蛋白抑制剂和新型HBV RNA去稳定剂已被证明可以纳入目前的护理标准和其他Arbutus临床候选药物的药物联合方案中，进一步支持了我们为慢性HBV患者提供治愈方案的目标。“

介绍包括：

    2018年4月12日下午4:30 - 4：45（CET），HBV治疗：临床前研究
    平行会议口头报告＃3503：“Rene Rijnbrand的”利用新的口服生物可用的研究试剂用于慢性乙型肝炎感染的临床前抗病毒药物组合研究：AB-506，下一代HBV衣壳抑制剂和AB-452，HBV RNA去稳定剂“ Arbutus Biopharma生物学副校长
     
    2018年4月12日下午5:00 -5：15（CET），HBV治疗：临床前研究
    平行会议口头报告＃2646：Amy Lee，Arbutus Biopharma研究高级总监，“在临床前模型中使用皮下施用的siRNA制剂AB-729持续抑制乙型肝炎病毒复制和抗原血症”

关于杨梅

Arbutus生物制药公司是一家上市（Nasdaq：ABUS）生物制药公司，致力于发现，开发和商业化治疗慢性乙型肝炎病毒（HBV）感染患者的治疗方法。杨梅正在开发多种药物候选药物，每种药物都有可能改善护理标准（SOC），并有助于治疗性联合用药方案改善患者结局并为HBV提供潜在治愈药物。欲了解更多信息，请访问www.arbutusbio.com。

newchinabok

ab423核衣壳可能效果不好，谈得少了。欧肝会，美肝会比亚肝会含金量高些

桦子

杨梅将在2018年EASL肝脏会议上口头报告HBV治疗临床前研究：
1. 新的口服生物试剂: AB-506，下一代HBV衣壳抑制剂和AB-452，HBV RNA去稳定剂用于慢性乙肝抗病毒 。
2. 使用皮下施用的siRNA制剂AB-729持续抑制乙型肝炎病毒复制和抗原血症.

antiHBVren

回复 桦子 的帖子

嗯，杨梅是有几个候选药在开发中